Predicine

As part of Predicine’s 10-year anniversary global celebration series, we are delighted to host the Predicine Liquid Biopsy Summit 2025 - South San Francisco!

We will share our latest progress in providing globally harmonized liquid and tissue biopsy solutions in the US and China to support global clinical trials and CDx development.

Program highlights:

• Targeted Therapy:

Liquid Biopsy for Drug Development — RAS, MTAP & Beyond

• ADCs & Immunotherapy:

Liquid Biopsy for Drug Development — PD1/VEGF & Beyond

• From China to the World:

Biomarker Enabled Acceleration of Global Clinical Trials

Please see the agenda below and RSVP to the live or virtual event followed by a live Predicine lab tour. Food and beverages will be provided

Approval Needed – RSVP for a spot: https://www.eventbrite.com/e/predicine-liquid-biopsy-workshop-tickets-1849090542589?aff=oddtdtcreator

Join us for a lunch and lab tour to Predicine in Hayward – 2-hour round trip travel and lunch included: https://www.eventbrite.com/e/predicine-lab-tour-tickets-1854548848529?aff=oddtdtcreator

At the SITC 2025, Predicine is showcasing how its’ comprehensive & ultra-sensitive liquid biopsy solutions accelerate global biomarker-driven drug development, including our harmonized genomics and genetics platform in China.

Learn more about:

• Patient Enrollment – Expand trial eligibility by detecting more biomarker-positive patients with ultra-deep sequencing (KRAS, MTAP, MET, EGFR, HER2, and beyond).

• MRD Detection & Monitoring – Compare personalized, and actionable mutation-based MRD with methylation-based MRD to assess recurrence risk and therapy response at high sensitivity.

• Resistance Mechanisms – Integrate cfDNA + cfRNA with genomics, epigenomics, and transcriptomics to capture heterogeneity and identify resistance drivers.

• Global Scalability – Access seamless global support with harmonized assays, rapid turnaround, reproducibility, and operational reach across US, EU, China, JP, and RoW.

• Cost-Effectiveness – Test more samples, generate richer molecular insights, and maximize value within trial budgets.

Talk with Predicine team and explore our genomics, epigenomics, and transcriptomics-based liquid biopsy solutions for global clinical trials targeting RAS, MTAP, PD1/VEGF, ADC etc.

📅 Schedule a meeting with our experts at booth #816 to learn how our liquid biopsy assays can enable your next trial. [email protected]/?ismsaljsauthenabled=true" rel="ugc" target="_blank">https://outlook.office.com/book/[email protected]/?ismsaljsauthenabled=true

Join Predicine at the World CB & CDx 2025 Summit at booth #42

Multi-omic liquid biopsy for CDx development and commercialization

At the World CB & CDx 2025 Summit, Predicine is showcasing how its’ comprehensive & ultra-sensitive liquid biopsy solutions accelerate biomarker-driven drug development and CDx launch across oncology.

What’s new:

• PredicineCARE for CDx commercialization with FDA Breakthrough, NY State permit, to PMA underway

• Genomic profiling using blood and urine to enable global clinical trials and CDx development

• Epigenomic methylation profiling for earlier readouts of therapy response and resistance

• RNA profiling to advance next-generation drug development through transcriptomic insights

Predicine’s platform is designed to support biomarker-driven drug development, from exploratory endpoints to pivotal studies.

📍 Join us at World CB & CDx 2025 Summit to explore collaborations that accelerate your biomarker programs.

📅 Schedule a meeting with our experts at booth #42 to learn how our liquid biopsy assays can enable your next trial.
[email protected]/?ismsaljsauthenabled=true" rel="ugc" target="_blank">https://outlook.office.com/book/[email protected]/?ismsaljsauthenabled=true

Today we’re proud to share that Predicine has officially submitted the first module of its PMA application to the FDA for PredicineCARE™, a urine cfDNA NGS assay, as a companion diagnostic (CDx) for bladder cancer. It’s inspiring to see our collective efforts driving meaningful progress in cancer diagnostics and patient care.

This foundational submission includes comprehensive documentation of the Predicine FDA-grade manufacturing and quality systems, paving the way for future CDx indications across our liquid biopsy and tissue-based platforms.

Learn more here: https://www.globenewswire.com/news-release/2025/09/02/3142717/0/en/Predicine-Submits-First-Module-of-PMA-Application-to-FDA-for-PredicineCARE-as-a-Companion-Diagnostic-Assay-in-Bladder-Cancer.html

Predicine Submits First Module of PMA Application to FDA for PredicineCARE™ as a Companion Diagnostic Assay in Bladder Cancer HAYWARD, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, today announced the submission of the first...